Galmed Pharmaceuticals Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Galmed Pharmaceuticals Ltd은 수익성이 있나요?
Galmed Pharmaceuticals Ltd에 부채가 있나요?
Galmed Pharmaceuticals Ltd의 발행 주식은 몇 주인가요?
주요 통계
이전 종가
--
시가
--
일일 범위
-
52주 범위
-
거래량
--
평균 거래량
2.1M
EPS(TTM)
-3.60
배당수익률
--
시가총액
--
GLMD란 무엇인가요?
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.